New hope for Hard-to-Treat cancers: GTAEXS617 enters human trials

NCT ID NCT05985655

Recruiting now Disease control Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called GTAEXS617 in people with advanced solid tumors (like lung, pancreatic, or ovarian cancer) that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 230 participants will take part in this early-phase trial.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast carcinoma fallopian tube neoplasm fallopian tube serous adenocarcinoma head and neck squamous cell carcinoma hormone receptor-positive breast cancer non-small cell lung carcinoma ovarian carcinoma ovarian serous adenocarcinoma pancreatic adenocarcinoma primary peritoneal carcinoma Squamous Cell Carcinoma of Head and Neck triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR BREAST CARCINOMA HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) HIGH-GRADE EPITHELIAL OVARIAN, PRIMARY PERITONEAL, OR FALLOPIAN TUBE CANCERS (HGSOC) HORMONE RECEPTOR POSITIVE [HR+] AND HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE [HER2-] BREAST CARCINOMA NON-SMALL CELL LUNG CANCER (NSCLC) PANCREATIC ADENOCARCINOMA PLATINUM-RESISTANT HIGH-GRADE EPITHELIAL OVARIAN, PRIMARY PERITONEAL, OR FALLOPIAN TUBE CANCERS (HGSOC) TRIPLE NEGATIVE BREAST CANCER (TNBC)

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

CHU Sart Tilman
RECRUITING

Liège, Belgium

Contact
Clinique Universitaires Saint-Luc
RECRUITING

Brussels, Belgium

Contact
GZA Ziekenhuizen - Campus Sint-Augustinus
RECRUITING

Antwerp, Belgium
Institute Jules Bordet
RECRUITING

Brussels, Belgium
Newcastle Upon Tyne NHS Foundation Trust
RECRUITING

Newcastle upon Tyne, United Kingdom

Contact
Oxford University Hospitals NHS Foundation Trust
RECRUITING

Oxford, United Kingdom

Contact
START Midwest
RECRUITING

Grand Rapids, Michigan, 49546, United States
START Mountain Region
RECRUITING

West Valley City, Utah, 84119, United States
START San Antonio
RECRUITING

San Antonio, Texas, 78229, United States
The Beatson West of Scotland Cancer Centre
RECRUITING

Glasgow, United Kingdom

Contact
The Christie NHS Foundation Trust
RECRUITING

Manchester, United Kingdom

Contact
UCL Hospitals NHS Foundation Trust
RECRUITING

London, United Kingdom

Contact
USC Norris Comprehensive Cancer Center
RECRUITING

Los Angeles, California, 90089, United States